星昊医药
(430017)
| 流通市值：30.59亿 | | | 总市值：30.80亿 |
| 流通股本：1.21亿 | | | 总股本：1.22亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 142,178,012.19 | 648,042,134.12 | 468,292,733.23 | 321,401,139.92 |
| 营业收入 | 142,178,012.19 | 648,042,134.12 | 468,292,733.23 | 321,401,139.92 |
| 二、营业总成本 | 120,618,943.06 | 560,748,586.74 | 411,245,882.53 | 275,641,314.58 |
| 营业成本 | 45,022,268.47 | 196,656,987.7 | 143,378,676.55 | 95,847,536.79 |
| 税金及附加 | 1,361,609.8 | 9,554,336.77 | 5,290,109.06 | 3,852,766.03 |
| 销售费用 | 48,521,710.02 | 227,469,918.47 | 173,411,913.91 | 117,552,272 |
| 管理费用 | 10,869,726.45 | 53,011,257.18 | 35,149,124.75 | 23,821,358.28 |
| 研发费用 | 16,467,401.12 | 77,844,094.79 | 57,186,846.22 | 37,460,384.88 |
| 财务费用 | -1,623,772.8 | -3,788,008.17 | -3,170,787.96 | -2,893,003.4 |
| 其中:利息费用 | 70,235 | 256,430.28 | 178,691.82 | 110,971.21 |
| 其中:利息收入 | 1,237,348.26 | 4,758,072.93 | 3,657,102.48 | 3,241,790.19 |
| 加:公允价值变动收益 | 1,139,383.56 | 3,860,704.13 | 3,308,786.3 | 3,533,261.66 |
| 加:投资收益 | 717,313.17 | 10,808,052.19 | 8,397,475.69 | 2,533,934.5 |
| 资产处置收益 | - | 0 | - | - |
| 资产减值损失(新) | -38,435.28 | -385,137.64 | -464,095.89 | -235,057.74 |
| 信用减值损失(新) | 331,325.57 | -4,056,918.06 | -648,125.71 | -548,843.92 |
| 其他收益 | 4,904,033.89 | 21,041,934.42 | 17,523,192.75 | 12,219,764.43 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 28,612,690.04 | 118,562,182.42 | 85,164,083.84 | 63,262,884.27 |
| 加:营业外收入 | 85,894.24 | 4,060,886.21 | 1,832,357.96 | 1,815,930.43 |
| 减:营业外支出 | 50,000 | 31,037,444.94 | 141,970.5 | 23,391.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 28,648,584.28 | 91,585,623.69 | 86,854,471.3 | 65,055,423.54 |
| 减:所得税费用 | 3,617,487.37 | 9,952,954.81 | 9,334,386.58 | 5,847,429.73 |
| 六、净利润 | 25,031,096.91 | 81,632,668.88 | 77,520,084.72 | 59,207,993.81 |
| 持续经营净利润 | 25,031,096.91 | 81,632,668.88 | 77,520,084.72 | 59,207,993.81 |
| 归属于母公司股东的净利润 | 25,031,096.91 | 82,882,732.47 | 78,770,148.31 | 60,428,636.94 |
| 少数股东损益 | - | -1,250,063.59 | -1,250,063.59 | -1,220,643.13 |
| (一)基本每股收益 | 0.2 | 0.68 | 0.64 | 0.49 |
| (二)稀释每股收益 | 0.2 | 0.68 | 0.64 | 0.49 |
| 八、其他综合收益 | 1,020.28 | 1,439,132.92 | -1,208.49 | 852.71 |
| 归属于母公司股东的其他综合收益 | 1,020.28 | 1,439,132.92 | -1,208.49 | 852.71 |
| 九、综合收益总额 | 25,032,117.19 | 83,071,801.8 | 77,518,876.23 | 59,208,846.52 |
| 归属于母公司股东的综合收益总额 | 25,032,117.19 | 84,321,865.39 | 78,768,939.82 | 60,429,489.65 |
| 归属于少数股东的综合收益总额 | - | -1,250,063.59 | -1,250,063.59 | -1,220,643.13 |
| 公告日期 | 2025-04-28 | 2025-04-23 | 2024-10-28 | 2024-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |